Goldman Sachs asks in biotech Report: Is curing patients a sustainable business? (2018)
1–10 of 188 posts
Re: Goldman Sachs asks in biotech Report: Is curing patients a sustainable business? (2018)
#2(2018)
Re: Goldman Sachs asks in biotech Report: Is curing patients a sustainable business? (2018)
#3No not really. Just allow euthanasia and be done with it. Yes. there are moral grounds to it. You don't want to live life, why can't you just do it peacefully?
I barely want to live another day of life at the age of 36 :/
Re: Goldman Sachs asks in biotech Report: Is curing patients a sustainable business? (2018)
#4The report-writer must have been from Goldman Sachs' B-team. It takes five minutes to turn up ample evidence which demonstrates that curing patients can be extremely profitable.
Take, for instance, Harvoni -- a drug introduced in late 2014 which cures Hepatitis C following a single course of treatment. It has done something like $100B in revenue for Gilead Biosciences, and, minimally, earned them $7-10B in profit. (Possibly much more than that.) Its pricing was scandalous, but that's not the issue here; the point is that it was unequivocally one of the most profitable drug launches in history.
Sure, the eradication of Hep C might make it "unsustainable" -- but it's not as though there's a lack of other diseases or maladies to contend with. Take the profits and plant new seeds, buy new technologies, develop new drugs. Besides, the research and development of new drugs has never been a stable business model, and never truly sustainable off one discovery, on account of patent expiry terms, generic competition, etc.
Re: Goldman Sachs asks in biotech Report: Is curing patients a sustainable business? (2018)
#5Meanwhile over in the world where the government sinks a lot of money and energy into its citizen's healthcare, government-funded labs are exploring permanent cures for all kinds of problems via genetic therapy.
But not here. Someone's gotta make mad bank off of every aspect of this shit here.
Re: Goldman Sachs asks in biotech Report: Is curing patients a sustainable business? (2018)
#6The report-writer must have been from Goldman Sachs' B-team. It takes five minutes to turn up ample evidence which demonstrates that curing patients can be extremely profitable. Take, for instance, Harvoni -- a drug introduced in late 2014 which cures Hepatitis C following a single course of treatment. It has done something like $100B in revenue for Gilead Biosciences, and, minimally, earned them $7-10B in profit. (P…
> Its pricing was scandalous
So if the pricing hadn't been "scandalous" by your definition, would it still have been profitable? You do realize that the profits are there because of the pricing, right?
Re: Goldman Sachs asks in biotech Report: Is curing patients a sustainable business? (2018)
#7It doesn’t matter if it is a sustainable business. People will do what they can to maximize their income now. If 10 companies are withholding a cure to milk the patients, any one of them can break from that strategy at any time, with near-instant financial reward and competitive advantage. It is not a stable equilibrium.
Re: Goldman Sachs asks in biotech Report: Is curing patients a sustainable business? (2018)
#8The report-writer must have been from Goldman Sachs' B-team. It takes five minutes to turn up ample evidence which demonstrates that curing patients can be extremely profitable. Take, for instance, Harvoni -- a drug introduced in late 2014 which cures Hepatitis C following a single course of treatment. It has done something like $100B in revenue for Gilead Biosciences, and, minimally, earned them $7-10B in profit. (P…
What is the significance of 7-10B if it is "possibly much more than that"? Even if it was $15 billion that's a 15% margin. How is that scandalous pricing?
Re: Goldman Sachs asks in biotech Report: Is curing patients a sustainable business? (2018)
#9socialized healthcare please and thank you.
Re: Goldman Sachs asks in biotech Report: Is curing patients a sustainable business? (2018)
#10It doesn’t matter if it is a sustainable business. People will do what they can to maximize their income now. If 10 companies are withholding a cure to milk the patients, any one of them can break from that strategy at any time, with near-instant financial reward and competitive advantage. It is not a stable equilibrium.
As long as government regulation prevents them from forming a cartel.